[Adequate restitution in primary hypothyroidism depending on levothyroxine formulations].

Rev Med Inst Mex Seguro Soc

Universidad Autónoma de Nuevo León, Facultad de Medicina, Subdirección de Investigación. Monterrey, Nuevo León, México

Published: October 2018

Background: The prevalence of primary hypothyroidism (PH) is around 3.8%-4.6% in general population. Out of patients under treatment with levothyroxine, approximately 40% show altered levels of thyroid-stimulating hormone (TSH).

Objective: To determine the prevalence of euthyroid sick syndrome in patients under treatment for PH in two local clinics, considering that the number of formulations of levothyroxine could be a contributing factor to the inadequate restitution.

Methods: Descriptive, comparative cohort conducted with PH patients who were treated with a stable dose of levothyroxine for at least six months. Patients treated with mixtures of liothyronine/levothyroxine, with postsurgical hypothyroidism, pregnant, breastfeeding or mentally ill were discarded. Medical clinic 1 was a public center that had only access to levothyroxine of 100 µg, and medical clinic 2 was a private clinic with access to 25, 50, 75 and 100 µg levothyroxine formulations.

Results: A total of 350 patients were evaluated. 190 patients were obtained at clinic 1, and 160 patients at clinic 2. At clinic 1, only 63% received the appropriate dose, while at clinic 2, 75% were medicated with the correct dose (p = 0.033).

Conclusion: In the public center, 39% of patients did not receive appropriate dose of levothyroxine; however, in the private clinic, which had more drug formulations, the percentage of patients lowered to 25%. Therefore, the number of formulations could be a factor for the risk of inadequate restitution.

Download full-text PDF

Source

Publication Analysis

Top Keywords

patients
9
primary hypothyroidism
8
patients treatment
8
number formulations
8
patients treated
8
dose levothyroxine
8
clinic
8
medical clinic
8
public center
8
100 µg
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Suven Life Sciences, Hyderabad, Telangana, India.

Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Biogen, Cambridge, MA, USA.

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of tau aggregates. Research in animal models has generated hypotheses on the underlying mechanisms of the interaction between Aβ and tau pathology. In support of this interaction, results from clinical trials have shown that treatment with anti-Aβ monoclonal antibodies (mAbs) affects tau pathology.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Sage Bionetworks, Seattle, WA, USA.

Background: There is an urgent need for new therapeutic and diagnostic targets for Alzheimer's disease (AD). Dementia afflicts roughly 55 million individuals worldwide, and the prevalence is increasing with longer lifespans and the absence of preventive therapies. Given the demonstrated heterogeneity of Alzheimer's disease in biological and genetic components, it is critical to identify new therapeutic approaches.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Fundacion Neuropolis, Zaragoza, Zaragoza, Spain.

Background: The therapeutic management of dementia with Lewy bodies (LBD) is a challenge given the high sensitivity to drugs in this disease. This is particularly sensitive with regard to the management of parkinsonism. In particular, treatment of motor symptoms with levodopa or dopaminergic agonists poses a risk of worsening cognitive and behavioral symptoms.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Clario, Philadelphia, PA, USA.

Background: Clinical outcome assessments (COAs) are an important part of clinical trials to measure what is meaningful to patients and caregivers. This study aimed to examine trends in Alzheimer's Disease (AD) COAs used in clinical trials, given the FDA's recent emphasis on patient-focused drug development and early AD.

Method: ClinicalTrials.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!